Blood-marker guided add-on treatment for major depression
Treatments studied
Part of Mental health clinical trials.
This study tests whether doctors can choose the best add-on immune-related treatment for people with major depressive disorder by using inflammation blood tests. It’s meant for people whose depression has not improved enough with their current antidepressant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 to 65 years old and can give consent and take pills by mouth
- You’ve been diagnosed with major depressive disorder by a structured interview, and this episode hasn’t improved on your current antidepressant
- Your antidepressant dose has been stable for at least 4 weeks (6 weeks for fluoxetine), and you don’t plan to change it during the study
- You don’t have certain other mental health conditions like bipolar disorder, psychosis, or substance/alcohol use disorder
- You’re not using medicines that strongly affect the immune system (such as immunosuppressants or immunostimulants) within the last 21 days
- If you can become pregnant, you agree to reliable birth control and a pregnancy test; you can’t be pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether two anti-inflammatory drugs, celecoxib and minocycline, can help treat depression. You may join if you have moderate to severe depression and are not at high risk for certain medical conditions or drug interactions.
This trial tests whether adding the antibiotic minocycline to your current antidepressant helps people with both depression and obesity. It aims to see if reducing inflammation can improve mood.
This trial tests a medication called tocilizumab, which targets inflammation, to see if it can improve symptoms of major depression in people with signs of inflammation. You may be eligible if you have depression with a high monocyte count and significant loss of interest or pleasure.
This trial tests if a medicine called infliximab, given through an IV, can help improve thinking and memory problems in people with moderate to severe depression who also have high inflammation levels. It aims to see if lowering inflammation can ease both mood and cognitive symptoms.
This early-stage study tests how your brain responds to an “inflammatory challenge” in people with major depressive disorder and in healthy volunteers. It may help researchers understand the immune-to-brain link in depression and guide future treatments.
This study tests whether certain immune markers and mood symptoms can help predict how well people will respond to antidepressants. Researchers hope to make treatment more personalized for people with depression.
Hear when a new Major Depressive Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.